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Cases of invasive mycosis due to Blastobotrys serpentis and B. proliferans identified by sequencing in a preterm patient and a
rhabdomyosarcoma patient, respectively, are reported. Both species revealed elevated fluconazole and echinocandinMICs by the
CLSI broth microdilution method. Additionally, B. serpentis exhibited high amphotericin B MICs, thus posing serious therapeu-
tic challenges.
CASE REPORTS
Case 1. A 29-week gestation preterm male infant at birth wasadmitted on 24 April 2013 because of respiratory distress. The
infant was born by normal vaginal delivery to a 24-year-old pri-
migravidamother. On admission at day 1, the child was not active
and had tachypnoeawith a respiratory rate of 68/min and his chest
X-ray showed mild haziness. Examination of the cardiovascular
system revealed no abnormal heart sounds and equal bilateral
peripheral pulses. The abdomen was soft, with no organomegaly
noted. On day 5, a loud murmur was detected and an echocardi-
ography revealed a large patent ductus arteriosus of 2.2mm in size
whichwas surgically closed.His total leukocyte countwas elevated
(24,000 cells/l), and his C-reactive protein level was 0.1 mg/liter.
Twodays later, the infant developed abdominal distension and the
X-ray revealed a pneumoperitoneum. This was managed with a
peritoneal drainage followed by laparotomy. During surgery, a
gangrenous gastric fundus with a sloughed greater curvature,
leading to an approximately 40% to 45% loss of stomach volume,
was seen. The necrotic tissues were removed; gastric anastomosis
was done with placement of a gastrojejunal feeding tube via gas-
trotomy. The child underwent operation twice again, on days 14
and 29 of admission, because of anastomotic leakage and perfora-
tion due to a gangrenous bowel.Histopathological examination of
tissue biopsy specimens of the distal ileum, terminal ileum, and
stoma showed active inflammatory changes, but no granuloma
and ganglion cells were present, ruling out Hirschsprung disease.
The child was empirically treated with ampicillin and gentamicin
starting from day 1 of admission along with prophylactic flucona-
zole (3 mg/kg of body weight twice weekly) due to a high risk for
invasive candidiasis. Further during the course of treatment,
meropenem therapy was included on day 3, cefoperazone-sulbac-
tam therapy a week later, and ofloxacin therapy on day 17. The
clinical course and the therapy instituted are depicted in Fig. 1.
Cultures of the discharge from the laprotomy incision site on day
15 of admission grew yeasts identified as Stephanoascus ciferrii
(identification, 86%) by the use of a Vitek2 yeast ID system (bio-
Mérieux, Marcy l’Etoile, France) which exhibited a high flucona-
zole MIC (64 g/ml) by AST-YS06 (bioMérieux). Blood cul-
tures in Bactec Peds Plus/F vials taken on days 16, 18, 21, 23, and
26 of admission grew fluconazole-resistant S. ciferrii after 2 to 3
days of incubation at 37°C. The endotracheal aspirate collected on
day 23 also grew S. ciferrii. The patient had already received flu-
conazole (6mg/kg) for 17 days; the treatment was then changed to
amphotericin B (1.5 mg/kg) due to clinical deterioration. Since
blood culture results continued to be positive, voriconazole (2
mg/kg twice daily) was added on day 5 to the amphotericin B
therapy. However, the neonate succumbed to the complications
of fungemia on day 31 of admission.
Case 2. An 8-year-girl was referred to a Regional Cancer Centre
after being diagnosed with rhabdomyosarcoma. The biopsy speci-
men from the nasal cavity showed a malignant round-cell neoplasm
consistent with rhabdomyosarcoma infiltrating the respiratory mu-
cosa and glandular tissue. During the course of chemotherapy, a pe-
ripherally inserted central catheter (PICC)wasplaced for administer-
ing chemotherapeutic drugs. Twomonths after PICC line insertion,
thepatientdeveloped feverwithoutany localizing features.Herblood
culture sent in a BacT/Alert bottle grew a Candida species. The iso-
late was misidentified as Stephanoascus ciferriiwith a low discrim-
ination profile by the use of a Vitek2 yeast ID system. The patient’s
PICC line was removed, and oral fluconazole (10 mg/kg/day) was
given for 2weeks.Her fever subsided, and shewas progressingwell
after 6 months of follow-up.
Mycological investigations. The isolates originating from
peritoneal and blood culture from case 1 (accession numbers
VPCI 568/P/13 and VPCI 569/P/13) and blood culture from case
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2 (accession number VPCI 573/P/13) were sent to the Mycology
Reference Laboratory, V. P. Chest Institute, Delhi, India. They
were identified as Blastobotrys serpentis and Blastobotrys prolifer-
ans from case 1 and case 2, respectively. A brief description of their
morphological, biochemical, andmolecular identification is given
below.
Morphological andbiochemical characteristics ofBlastobot-
rys spp. (i)Blastobotrys serpentis.The clinical isolates (VPCI 568/
P/13 andVPCI 569/P/13), along with the type strain of B. serpentis
(CBS 10541T), revealed wrinkled white yeast-like colonies which
showedmultilateral budding and occasionally spherical yeast cells
after 4 days of incubation at 28°C on potato dextrose agar (PDA).
They revealed abundant, well-differentiated pseudohyphae with
blastoconidia after 5 days of incubation at 28°C on rice Tween 80
agar (Fig. 2a). Septate hyphae were not observed. Also, the isolates
grew in the presence of 0.01% cycloheximide and grew weakly on
50% glucose whereas the growthwas inhibited on 6.5%NaCl. The
carbon and nitrogen assimilation profiles of the isolates were de-
termined by the microplate technique with yeast nitrogen base
and yeast carbon base (Difco) (http://www.cbs.knaw.nl/yeast), re-
spectively. The microtiter plates containing the medium were in-
oculated with 50l of yeast inoculum (1:10MacFarland standard
no. 2) into each well and incubated at 25°C for 3 to 5 days without
agitation. The readings were taken by spectrophotometer (Spec-
traMax Plus; Molecular Devices) at 405 nm after shaking. Table 1
lists the assimilation profiles of Blastobotrys serpentis isolates. No-
tably, Blastobotrys serpentis clinical isolates, along with the type
strain, grew at 37°C and 40°C.
(ii) Blastobotrys proliferans. The VPCI 573/P/13 isolate
showed dry, hairy, white colonies on potato dextrose agar (PDA)
after 4 days of incubation at 28°C. Slide cultures of 7 days growth
on malt extract agar at 28°C showed conidiophores bearing pear-
shaped mother cells (Fig. 2b). The mother cells were single, and
each was crowned with secondary conidia (Fig. 2b). In addition,
globose, lateral conidia and hyaline, thick-walled terminal and
intercalary chlamydospores were observed (Fig. 2c). Like B. ser-
pentis, B. proliferans assimilated sugars such as D-glucose, D-galac-
tose, D-xylose, maltose, etc., but failed to assimilate nitrate (Table
1). However, unlike B. serpentis, this species grew in the presence
of melibiose. Also, the isolate revealed growth at 37°C.
In vitro antifungal susceptibility testing. In vitro antifungal
susceptibility testing of all isolates was done using the Clinical and
Laboratory Standards Institute broth microdilution method, fol-
lowing the CLSI M27-A3 guidelines (1). The antifungals tested
were amphotericin B (Sigma, St. Louis, MO), fluconazole (Pfizer,
Groton, CT), itraconazole (Lee Pharma, Hyderabad, India), vori-
conazole (Pfizer), posaconazole (Merck,Whitehouse Station,NJ),
isavuconazole (Basilea Pharmaceutica, Basel, Switzerland), 5-flu-
cytosine (Sigma), caspofungin (Merck), micafungin (Astellas,
Toyama, Japan), and anidulafungin (Pfizer). Candida krusei
(ATCC 6258) and Candida parapsilosis (ATCC 22019) were used
as quality control strains. The MIC endpoints were defined as the
lowest drug concentrations that caused a prominent (50%) de-
crease in growth vis-à-vis the controls and were read visually after
24 h for azoles and echinocandins as recently validated by Pfaller
et al. (2, 3, 4). For amphotericin B, the MIC was defined as the
lowest concentration at which there was 100% inhibition of
growth compared with the drug-free control well results. The in
vitro antifungal susceptibility data for both the species are pre-
sented in Table 2. Blastobotrys serpentis (VPCI 568/P/13 and VPCI
569/P/13) isolates exhibited high fluconazole, amphotericin B,
caspofungin, micafungin, and anidulafunginMICs. They had low
isavuconazole, itraconazole, voriconazole, 5-flucytosine, and po-
saconazoleMICs. However,B. proliferansVPCI 573/P/13 revealed
reduced susceptibility to all the antifungals tested except ampho-
tericin B (MIC, 0.125 g/ml).
Sequencing of ITS and D1/D2 regions. Genomic DNA was
extracted from all of the test yeast isolates as described by Xu et al.
(5). Extracted DNA was amplified using the ITS-1 (5=-TCCGTA
GGTGAACCTTGCGG-3=) and ITS-4 (5=-TCCTCCGCTTATTG
ATATGC-3=) primers, which amplify the internal transcribed
spacer (ITS) region of the ribosomal subunit, and the NL-1 (5=-G
FIG 1 The drugs administered and the clinical course of a case 1 neonate with invasive mycosis due to Blastobotrys serpentis. ve, positive; ET, endotracheal
aspirate.
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CATATCAATAAGCGGAGGAAAAG-3=) and NL-4 (5=-GGTCC
GTGTTTCAAGACGG-3=) primers, which amplify the 600-bp
D1/D2 region of the large ribosomal subunit (6, 7). Amplified
DNA was sequenced in both strands on an ABI 3130XL Genetic
Analyzer (Applied Biosystems, Foster City, CA) using a BigDye
Terminator kit, v3.1 (Applied Biosystems). Sequences were
aligned using Sequencing Analysis 5.3.1 software (Applied Biosys-
tems). GenBank basic local alignment search tool (BLAST)
searches (http://www.ncbi.nlm.nih.gov/BLAST/Blast.cgi) were
performed for species identification. ITS and D1/D2 region se-
quences of the two isolates VPCI 568/P/13 and VPCI 569/P/13
from case 1 showed 99% homology (query coverage, 99%) with
Candida sp. strain YSW113A (GenBank accession no. AM410670
[ITS] and AM410667 [D1/D2]), which was named species nov.
Blastobotrys serpentis in 2008 (8). However, the ITS and D1/D2
region sequences of isolateVPCI 573/P/13 showed 99%homology
(query coverage, 99%) with those of Blastobotrys proliferans CBS
522.75T (accession no. EU343812 [ITS] andDQ442684 [D1/D2]).
For phylogenetic analyses, the D1/D2 region sequences of the
type and reference strains of B. serpentis CBS 10541T and W113B
and B. proliferans CBS 522.75T, along with those of B. chiroptero-
rum CBS 6064T and Trichomonascus ciferrii CBS 5295 (synonym
Stephanoascus ciferrii), were retrieved from theNCBI database. The
sequences of the test and reference isolates were aligned using the
ClustalW program (version 1.82) (9), and the final alignments
were edited manually. A maximum-likelihood tree based on
D1/D2 gene sequences using 2,000 bootstrap replications was
constructed using MEGA version 5 (10). The phylogenetic tree
enabled the differentiation of B. serpentis and B. proliferans from
each other and from the closely related species B. chiropterorum
with a good bootstrap support value (99%). Trichomonascus cifer-
rii was also classified apart from clusters of both of the species
(Fig. 3).
Fungal infections due to species of Blastobotrys are extremely
rare, and a solitary case of peritonitis due to B. proliferans in a
patient undergoing continuous ambulatory peritoneal dialysis is
on record (11). Recently, the role of B. rhaffinosifermentans caus-
ing a significant airway inflammation in a cystic fibrosis patient
before lung transplant and pleural space infection post-lung
transplant was highlighted (12). The genus Blastobotrys von Klo-
potek (1967) was originally treated as a hyphomycete, and it was
believed to be closely related to the genus Sporothrix, from which
it was distinguished on the basis of morphological criteria (13).
On the basis of the D1/D2 large-subunit (LSU) rRNA gene se-
quences, Kurtzman and Robnett placed the genus Blastobotrys in
the saccharomycetales and suggested that Blastobotrys, Arxula,
and Sympodiomyces may represent the same anamorphic genus
(14). Later, this suggestion was confirmed using multilocus anal-
ysis and the species Arxula and Sympodiomyces were therefore
transferred to the Blastobotrys genus (teleomorph Trichomonas-
cus) (14). The two species of Blastobotrys reported here, viz., B.
serpentis and B. proliferans, were initially misidentified as Stepha-
noascus ciferrii by the use of a Vitek2 system. Kurtzman and Rob-
nett, by using multigene analysis in 2007, showed that Stephano-
ascus cifferii (synonym Candida cifferii) is in the Trichomonascus
clade, and the genus Stephanoascus became a synonym of
Trichomonascus (14). However, this taxonomic yeast nomencla-
FIG 2 (a) Slide cultures on malt extract agar of 5 days growth at 28°C of the Blastobotrys serpentis (VPCI 568/P/13) isolate collected from blood culture of case
1, showing well-differentiated pseudohyphae with abundant blastoconidia. Septate hyphae were not observed.Magnification,1,000. (b) Slide cultures onmalt
extract agar of 7 days growth at 28°C of theBlastobotrys proliferans (VPCI 573/P/13) isolate collected fromblood culture of case 2, showing conidiophores bearing
pear-shapedmother cells and crowned with secondary conidia (downward arrow) and lateral conidia (upward arrows). Magnification,400. (c) Thick-walled,
terminal, and intercalary chlamydospores (arrows). Magnification,1,000.
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ture change has clearly not been updated in the Vitek2 system
database.
Case 1 reported here involved a severely immunocompro-
mised neonate who had undergone multiple surgeries due to in-
TABLE 1 Assimilation profile and growth characteristics of Blastobotrys
serpentis and B. proliferans
Characteristic or condition
Resulta
B. serpentis (n 2
sources [peritoneal
wound swab, blood])
B. proliferans (n 1
source [blood])
Carbon assimilation
D-Glucose  
D-Galactose  
L-Sorbose  
N-Acetyl-glucosamine  
D-Ribose  
D-Xylose  
L-Arabinose  
L-Rhamnose  
Sucrose  
D-Maltose  
D-Trehalose  
D-Cellobiose  
D-Melibiose  
D-Mannose  
D-Melezitose  
Lactose  	
D-Sorbitol  
Raffinose  
Gentiobiose  
Palatinose  
D-Melezitose  
Glycerol  
Erythritol  
Xylitol  
Inositol  
D-Gluconate  
L-Lactate  
Citrate  
L-Malate  
D-Galactouronate  
Acetate  
Urease  
Glucuronate  
2-Keto-D-gluconate 
Nitrogen assimilation 
Nitrate  
L-Lysine  
Leucine  
Arginine  	
Tyrosine  
L-Proline 
Growth under different
conditions

37°C  
40°C  
0.01% cycloheximide  
0.1% cycloheximide  Wc
50% glucose W 
6.5% NaCl 
a, growth;, no growth; W, weak growth.
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testinal perforation and developed persistent fungemia due to B.
serpentis, which was isolated from multiple blood cultures, peri-
toneal drainage, and endotracheal aspirate. Blastobotrys serpentis
has never previously been reported as an etiologic agent of inva-
sive mycoses in humans. However, the species was first described
in 2008 as a novel member of genus Blastobotrys isolated from the
intestine of a dead trinket snake in India (8). Notably, both species
of Blastobotrys reported here, i.e., B. proliferans and B. serpentis,
had reduced susceptibility to commonly used antifungals, i.e., flu-
conazole and caspofungin. Additionally, B. serpentis isolates had
relatively high anidulafungin (0.5 g/ml) and micafungin (0.25
g/ml) MICs, considering that the recent epidemiological cutoff
values for 5 Candida species, barring C. parapsilosis, for both the
echinocandins range from0.03 to 0.25g/ml (4). Furthermore,B.
serpentis also exhibited high amphotericin B MICs, thus raising
serious concerns about the therapeutic options for patients with
Blastobotrys infections. Due to the rarity of clinical cases of infec-
tion by Blastobotrys, there is paucity of information on the suscep-
tibility data of this genus. In the present report of case 1, the new-
born developed breakthrough fungemia due to B. serpentis while
he was on fluconazole prophylaxis and could not be successfully
treated with amphotericin B, for which the isolate had highMICs.
The neonate had all the risk factors reported for development of
candidemia, including prematurity, prolonged antibiotic treat-
ment, total parenteral nutrition, mechanical ventilation, and an
extended stay in the neonatal intensive care unit (15). Case 2 with
fungemia due to B. proliferans probably responded to removal of
the PICC line. Although the patient was also treated with flucona-
zole, the isolate showed a high (64 g/ml) fluconazole MIC. Pre-
viously, Quirin et al. reported that B. proliferans isolated from a
case of peritonitis showed decreased susceptibility to all antifun-
gals tested, except amphotericin B (11). Similarly to our experi-
ence, the removal of the Tenckhoff catheter and administration of
oral fluconazole resulted in a successful outcome in the case re-
ported by Quirin et al. (11). Notably, B. rhaffinosifermentans also
had reduced susceptibility to fluconazole in a recently reported
case (12). The patient was treated successfully with aggressive an-
tifungal therapy, includingmultiple courses of intravenous caspo-
fungin, oral voriconazole, and nebulized L-amphotericin B ex-
tending for 22 months (12). The sources of both Blastobotrys
species in the present cases remain enigmatic, especially in the
newborn, who possibly acquired the infection while in the hospi-
tal, whereas in case 2, the childmay have obtained the fungus from
her surroundings, as B. proliferans has been previously isolated
from garden soil and house dust (13). However, B. serpentis has so
far been reported to have been isolated only from the gut of a dead
snake in a zoo in India, suggesting that the yeasts of the genus
Blastobotrys may be acquired by humans and animals from the
environment (8).
Of the 21 species of Blastobotrys previously described in a tax-
onomic study of yeasts (13), 12were reported to grow at 37°C, and
these three species, namely,B. proliferans,B. chiropterorum, andB.
rhaffinosifermentans, have been isolated from humans (11–13,
16).Notably, a report in the latest edition of amonograph describ-
ing yeasts (13) asserting that growth of the B. serpentis type strain
(CBS 10541) is negative at 37°C is erroneous, as it, along with the
two clinical strains (VPCI 568/P/13 and VPCI 569/P/13), showed
luxuriant growth at 37°C in the present study. Furthermore, spe-
cies of the genus Blastobotrys reveal diverse morphological and
biochemical characteristics and are therefore difficult to identify
by standard mycological procedures in routine laboratories. Ad-
ditionally, they exhibit reduced susceptibility to antifungals.
Therefore, any significant clinical yeast isolate originating from
sterile sites which is identified as Stephanoascus ciferrii by the
Vitek2 system should be evaluated further by molecular tech-
niques and in vitro antifungal susceptibility testing should be per-
formed. Finally, the emergence of Blastobotrys spp. as opportunis-
tic fungal pathogens capable of causing invasive disease, with
reduced susceptibility to antifungals, is noteworthy, as it poses
serious diagnostic and therapeutic challenges.
Nucleotide sequence accession numbers. VPCI 568/P/13,
VPCI 569/P/13, and VPCI 573/P/13 ITS sequences were submit-
ted to GenBank with accession numbers KM056339, KM056340,
and KM056341, respectively, and LSU sequences with accession
numbers KM056336, KM056337, and KM056338, respectively.
The 2 strains B. serpentis VPCI 568/P/13 and B. proliferans VPCI
573/P/13 were deposited in the CBS-KNAW Fungal Biodiversity
Centre, The Netherlands, with accession numbers CBS 13871 and
CBS 13872, respectively.
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